BIIB131
Appearance
Names | |
---|---|
IUPAC name
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid
| |
Other names
| |
Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
| |
| |
Properties | |
C51H68N2O10 | |
Molar mass | 869.109 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
BIIB131 (also known as SMTP-7 or TMS-007) is a prothrombolytic small-molecule drug developed by Biogen for acute ischemic stroke.[1][2][3]
References
[edit]- ^ Yuan, Long; Jiang, Di; Pinkham, Andrew; Kirkland, Melissa (November 2023). "Development, validation and application of a capillary microsampling LC–MS/MS method for the quantification of BIIB131 (SMTP-7) in rat plasma". Journal of Pharmaceutical and Biomedical Analysis. 236: 115752. doi:10.1016/j.jpba.2023.115752. PMID 37769527.
- ^ Kostrubsky, Vick; Liu, Ying; Muste, Cathy; Gu, Chungang; Kirkland, Melissa; Nishimura, Naoko; Hasegawa, Keiko; Hasumi, Keiji; Yuan, Long (December 2023). "Preclinical safety, toxicokinetics and metabolism of BIIB131, a novel prothrombolytic agent for acute stroke". Regulatory Toxicology and Pharmacology. 145: 105498. doi:10.1016/j.yrtph.2023.105498. PMID 37778433. S2CID 263297651.
- ^ Wang, Bo; Lin, Yiqing (2022). "Absolute configuration determination of SMTP-7 via microcrystal electron diffraction (MicroED)". Chemical Communications. 58 (94): 13071–13074. doi:10.1039/D2CC05218K. PMID 36305866. S2CID 253184088.